SPECIAL NOTICE
A -- Development & Commercialization of NITRIC OXIDE-RELEASING DRUGS AND BIOMATERIALS
- Notice Date
- 5/29/2002
- Notice Type
- Special Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bldg 427 Room 12, Frederick, MD, 21702
- ZIP Code
- 21702
- Solicitation Number
- Reference-Number-01594
- Response Due
- 6/24/2002
- Archive Date
- 7/9/2002
- Point of Contact
- Bonnie Chamberlain, Marketing Coordinator, Phone (301)435-3134, Fax (301)402-2117, - Bonnie Chamberlain, Marketing Coordinator, Phone (301)435-3134, Fax (301)402-2117,
- E-Mail Address
-
chamberbo@mail.nih.gov, chamberbo@mail.nih.gov
- Description
- NIH scientists are developing a variety of novel techniques for delivering nitric oxide (NO) to specific organs and cell types for therapeutic benefit. Methods for targeting lung, liver, and other tissues have been introduced to the literature, as have NO-releasing proteins and insoluble polymers. The compounds and drug delivery strategies developed thus far have shown promising activities that have been demonstrated in relevant experimental animal models. These include inhibition of thrombosis, treatment of vasospasm, relief of respiratory distress, protection against toxic liver injury, radiosensitization of hypoxic tumors, correction of genitourinary tract dysfunction, antimicrobial effects, protection against ischemia-reperfusion injury and whole-body radiation, and preservation of organ transplants. The National Cancer Institute (NCI) seeks Licensee(s) and/or Cooperative Research and Development Agreement (CRADA) Collaborator(s) for the development and commercialization of Nitric Oxide (NO)-Releasing Drugs and Biomaterials as embodied in a variety of recent NCI publications, as well as, in the patents and patent applications listed below. Each Party?s Contributions to CRADA: The role of the National Cancer Institute in this CRADA will include, but not be limited to: 1. Providing intellectual, scientific, and technical expertise and experience to the research project. 2. Providing the Collaborator with samples of the subject compounds for pharmacological evaluation. 3. Planning research studies and interpreting research results. 4. Providing support services at NCI/CCR. 5. Publishing research results. The role of the CRADA Collaborator may include, but not be limited to: 1. Providing significant intellectual, scientific, and technical expertise or experience to the research project. 2. Planning research studies and interpreting research results. 3. Providing support for ongoing CRADA-related research in the development of the particular application of nitric oxide-releasing drugs/biomaterials outlined in the Agreement: a. Financial support to facilitate scientific goals; b. Technical or financial support for further design of applications. 4. Publishing research results. Terms/Licensing Potential/Patent Status: A Cooperative Research and Development Agreement (CRADA) is the anticipated joint agreement to be entered into with NCI pursuant to the Federal Technology Transfer Act of 1986 and Executive Order 12591 of April 10, 1987, as amended. A CRADA is an agreement designed to enable certain collaborations between Government laboratories and non-Government laboratories. It is not a grant, and it is not a contract for procurement of goods/services. The NCI is prohibited from transferring funds to a CRADA collaborator. Under a CRADA, NCI can contribute facilities, staff, materials, and expertise. The CRADA Collaborator will have an option to negotiate the terms of an exclusive or nonexclusive commercialization license to subject inventions arising under the CRADA. CRADA applicants should be aware that a license to the above-mentioned patent rights may be necessary in order to commercialize products arising from a CRADA. The expected duration of the CRADA(s) would be for up to five (5) years. The goals of CRADAs include rapid publication of research results and timely commercialization of products, diagnostics, and treatments that result from the research. Selection Criteria: 1. The ability to collaborate with NCI on further research and development of this technology. This ability can be demonstrated through experience and expertise in this or related areas of technology indicating the ability to contribute intellectually to ongoing research and development. 2. The demonstration of adequate resources to perform the research, development and commercialization of this technology (e.g., facilities, personnel and expertise) and accomplish objectives according to an appropriate timetable to be outlined in the CRADA Collaborator?s proposal. 3. The willingness to commit best effort and demonstrated resources to the research, development and commercialization of this technology. 4. The demonstration of expertise in the commercial development, production, marketing and sales of products related to this area of technology. 5. The level of financial support the CRADA Collaborator will provide for CRADA-related Government activities. 6. The willingness to cooperate with the NCI in the timely publication of research results. 7. The agreement to be bound by the appropriate DHHS regulations relating to human subjects, and all PHS policies relating to the use and care of laboratory animals. 8. The willingness to accept the legal provisions and language of the CRADA with only minor modifications, if any. These provisions govern the equitable distribution of patent rights to CRADA inventions. Generally, the rights of ownership are retained by the organization that is the employer of the inventor, with (1) the grant of license for research and other Government purposes to the Government when the CRADA Collaborator?s employee is the sole inventor, or (2) the grant of an option to elect an exclusive or nonexclusive license to the CRADA Collaborator when the Government employee is the sole inventor. Contact Informaiton: CRADA information may be obtained by contacting Dr. Charmaine Richman, Technology Transfer Specialist, Technology Transfer Branch, National Cancer Institute, 1003 West Seventh Street, Suite 500, Frederick, Maryland 21701; telephone: 301-846-5465; fax 301-846-6820; e-mail: richmanc@mail.nih.gov. Scientific inquiries may be directed to contacting Dr. Larry Keefer, National Cancer Institute/Center for Cancer Research (CCR) at Frederick, Building 538, Room 205F, Frederick, MD 21702-1201; telephone : 301-846-1467; e-mail: keefer@ncifcrf.gov.
- Record
- SN00084494-W 20020531/020529213126 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |